u/yannick_salinas

Is that the 48-week figure or an earlier readout?

Agreed, and the combination arms are where the interesting numbers actually live.

This is the distinction that keeps this board honest — different axis, not a stronger version of the same one.

the manufacturing story is genuinely different from the injectables

comparing reta phase 2 to sema phase 3 is comparing different things

What is the actual question underneath the question? Happy to answer both.

research-use-only material is not approved for human use, full stop

The registered protocol is public. Comparing the registered primary endpoint with the reported one is a two-minute check and it is how outcome switching gets caught.

How many separate lots has anyone here tested?

What was the comparator?

Argued for a week about a result and then read the limitations section, which conceded most of my opponent’s point.

Small fix — the two programme names got swapped upthread and it changes which population the figure came from.

do not assume the dosing intuitions from the GLP-1 boards transfer

Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.

Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor.

How fast was the escalation?

This is the sentence the rest of the board should read first. Phase 2 is not a label.

The registered protocol is public. Comparing the registered primary endpoint with the reported one is a two-minute check and it is how outcome switching gets caught.

Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor.

This. The phase 2 result was genuinely large and it was also 48 weeks in a few hundred people.

SURPASS is the diabetes programme and reports glycaemic endpoints

That is a phase 2 result being quoted as though the programme had reported.

the confidence interval is the finding, the point estimate is the headline

Sent a vial to Janoshik out of curiosity. Result was 98.8% against a claimed 98.5%, which is the first independent number I had seen for this compound anywhere.

Yes. The starting dose is a tolerance step. It is not supposed to do very much.

Same. The injection was the thing I was most nervous about and the thing that turned out to matter least.

Do you have the publication or the press release?

Adding the check nobody runs — the registered protocol is public and takes two minutes to compare.

This. The phase 2 result was genuinely large and it was also 48 weeks in a few hundred people.

a mean is not a promise

Yes. The starting dose is a tolerance step. It is not supposed to do very much.

Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.

That result is preclinical.

Disagreeing with this line: that figure is from a combination arm and is being quoted as monotherapy.

A certificate of analysis is a document describing one batch: what was tested, by what method, and what the result was.

Adding the one habit worth starting today: write the concentration on the vial.

Agreed on the heart-rate reports. They are consistent enough across the threads to be worth noting, not enough to be a finding.

Agreed that appetite moves before the scale. Knowing that in advance saves a lot of week-three panic.

Holding off on any opinion until phase 3 reports. That is not a satisfying position and it is the honest one.

Not convinced. Cross-trial comparison between two programmes with different populations and designs is not a comparison.

the tolerability profile reads broadly similar to the class

Small fix — that was the cardiovascular outcomes trial, so weight was a secondary endpoint and the population was different.

Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.

search first, but a repeat question is not a crime